Datapoint: AstraZeneca’s Saphnelo Cleared to Treat Lupus

The FDA on Monday approved AstraZeneca’s Saphnelo for the treatment of moderate to severe systemic lupus erythematosus (SLE), the most common form of the disease. The type I interferon receptor antagonist is the first approval for SLE since 2011, when GlaxoSmithKline’s Benlysta entered the market. While Saphnelo could pose a threat, Benlysta is highly advantaged in the SLE market basket. Its intravenous form holds covered or better status for 94% of all insured lives under the medical benefit vs. 65% of lives under the pharmacy benefit.

SOURCE: MMIT Analytics, as of 8/2/21

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 25

Datapoint: Kaiser Dominates 2022 Star Ratings

https://www.mmitnetwork.com/wp-content/uploads/2021/08/post-default-img.jpg
October 18

Datapoint: AmeriHealth Caritas to Enter Exchange Market

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 14

Datapoint: Ochsner to Launch MA Org in Louisiana

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today